Returning Patient Data in Rare Disease Studies

Returning individual results to participants is gaining momentum as a core expression of patient-centered research. In rare disease development, where participants often contribute significant time, personal risk, and emotional investment, access to personal study data is increasingly seen as part of a respectful and transparent research relationship. When done thoughtfully, it reinforces trust, deepens engagement, and supports continuity of care beyond the trial itself.

At the same time, returning results introduces complexity. Rare disease trials frequently generate exploratory data, biomarker findings, or intermediate outcomes that may not yet have established clinical meaning. Sponsors must therefore navigate a careful balance between transparency and unintended harm, ensuring that information is shared responsibly and with appropriate context.

Framing the Purpose of Data Return

Effective data-return strategies start with clarity of purpose. For many participants, personal results provide validation that their contribution mattered and offer insight into their own health journey. For sponsors, well-designed return processes can strengthen relationships with patient communities and reinforce long-term trust.

Data return is most impactful when it:

• Respects participant autonomy and their interest in information
• Acknowledges the personal investment involved in rare disease participation
• Supports informed conversations with treating clinicians
• Reinforces transparency and ethical responsibility

Building around these principles helps align expectations from the outset.

Evolving Legal and Policy Expectations

Alongside ethical arguments, expectations are beginning to appear in law and regulation in some regions.

Forthcoming UK clinical trials legislation, for example, will introduce a legal requirement to offer trial findings to participants within a defined timeframe and in language they can understand, reflecting a broader research transparency agenda.

In the European context, data-return discussions increasingly reference participants’ rights to be informed and to access their personal data, rooted in data protection law. Initiatives such as FACILITATE build on these rights to frame data return as part of respecting informational self-determination rather than a discretionary benefit.

Globally, there is still no single, harmonized legal requirement to return all individual trial data. However, funders, regulators, and ethics bodies are converging on a common expectation: that participants should at least be offered understandable information about the studies they enable, and that processes for returning more granular data be considered proactively rather than reactively.

Designing the Return Process

Planning for data return should be integrated into study design rather than treated as an end-of-trial add-on. This includes decisions about what information will be shared, how it will be delivered, and who will guide participants through it.

Core design considerations include:

• Scope of Data Returned – e.g., selected individual measures, key safety or efficacy findings, and/or aggregate trial results
• Timing – whether results are shared during the study, after database lock, or once primary results are publicly available
• Delivery Method – secure portals, mailed summaries, or clinician-mediated conversations
• Choices for Participants – the option to receive or decline results, and to change that preference over time
• Comprehension Safeguards — ensure returned results are clearly explained in plain language, include appropriate context and limitations, and provide a point of contact to prevent misinterpretation and unnecessary anxiety

In some cases, certain data may be withheld or shared at a later time due to regulatory requirements, data validation status, or the need to protect ongoing development or submission strategies.

Thinking through these elements early helps ensure that commitments made in consent forms and protocols can be operationalized in practice.

Operational Readiness and Governance

Finally, returning data requires practical infrastructure and governance. Sponsors and sites need to manage how results are generated, validated, stored, and released, and how participant preferences are recorded over time.

Operational readiness often involves:

• Clear roles and responsibilities between sponsor and sites
• Secure systems for storing and delivering participant-level results
• Processes to track who has received which information and when
• Alignment with consent language and data protection commitments

Integrating these elements into overall trial planning reduces friction at closeout and supports a smoother, more consistent experience for participants.

The Evolving Expectation

As clinical research moves toward greater transparency, returning patient data is shifting from “nice to have” toward a norm—particularly in engaged rare disease communities. For sponsors, the question is less whether to return data and more how to do so in a way that is ethically sound, operationally feasible, and aligned with emerging legal and regulatory expectations.

When thoughtfully designed, data return supports a more equitable, respectful, and collaborative rare disease research ecosystem that values not only the data generated but the people who make that data possible.

Explore how Premier Research partners with sponsors to embed transparency, governance, and participant trust into rare disease trial design. Contact us to discuss your next program.

ABOUT PREMIER RESEARCH:

Premier Research International LLC (Premier) is a global leader in clinical research and consulting services with expertise in driving an efficient and effective path to market for the life sciences industry.

Premier is built with the needs of biotech in mind, turning breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value.

Leveraging deep therapeutic expertise, innovative technology, and product development operational proficiency—from preclinical planning to clinical trial execution and commercialization—our integrated approach offers personalized, end-to-end solutions to identify the pertinent data and insight necessary to make informed decisions earlier and deliver accelerated development timelines for a smarter, faster path to approval. To learn more, visit premier-research.com.

REFERENCES:

• Kent, D. A., Villegas-Downs, M., Rios, M. D., Freedman, M., Krishnan, J. A., Menchaca, M. G., Patil, C. L., Sculley, J., Tintle, N., & Gerald, L. B. (2024). Returning individual research results to participants: Values, preferences, and expectations. Journal of Clinical and Translational Science, 8(1), Article e126. https://doi.org/10.1017/cts.2024.568  
• Hoffmann, E., et al. (2024). Return of participant-level clinical trial results to participants: Pilot of a simplified centralised approach. BMJ Open, 14(3), e080097. https://doi.org/10.1136/bmjopen-2024-e080097  
• Staunton, C., et al. (2024). Ethical framework for FACILITATE: A foundation for the return of clinical trial data to participants. Frontiers in Medicine, (2024). https://doi.org/10.3389/fmed.2024.1408600  
• National Academies of Sciences, Engineering, and Medicine. (2015). Sharing clinical trial data: Maximizing benefits, minimizing risk. The National Academies Press. https://doi.org/10.17226/18998 nap.nationalacademies.org